Media coverage about Quidel (NASDAQ:QDEL) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Quidel earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.914834857202 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

Several analysts have issued reports on QDEL shares. Piper Jaffray Companies upgraded Quidel from a “neutral” rating to an “overweight” rating and upped their target price for the company from $35.00 to $50.00 in a report on Tuesday, September 19th. Raymond James Financial restated a “buy” rating and issued a $47.00 target price (up from $41.00) on shares of Quidel in a report on Tuesday, September 19th. Barclays restated a “buy” rating and issued a $45.00 target price (up from $39.00) on shares of Quidel in a report on Tuesday, September 19th. Canaccord Genuity restated a “buy” rating and issued a $48.00 target price (up from $42.00) on shares of Quidel in a report on Tuesday, September 19th. Finally, Zacks Investment Research upgraded Quidel from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 27th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $48.80.

Quidel (NASDAQ QDEL) opened at $39.15 on Friday. Quidel has a 12 month low of $18.25 and a 12 month high of $45.55. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.68 and a current ratio of 6.28.

Quidel (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.21). Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The business had revenue of $50.89 million during the quarter, compared to analyst estimates of $50.47 million. During the same period last year, the company earned $0.10 EPS. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. equities research analysts anticipate that Quidel will post 0.6 EPS for the current year.

In related news, CEO Douglas C. Bryant sold 36,000 shares of the stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $42.91, for a total transaction of $1,544,760.00. Following the transaction, the chief executive officer now owns 296,493 shares of the company’s stock, valued at approximately $12,722,514.63. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Douglas C. Bryant sold 12,000 shares of the stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $42.17, for a total value of $506,040.00. Following the transaction, the chief executive officer now directly owns 296,493 shares in the company, valued at approximately $12,503,109.81. The disclosure for this sale can be found here. In the last three months, insiders have sold 147,530 shares of company stock worth $5,960,736. 22.00% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/02/quidel-qdel-receiving-somewhat-favorable-press-coverage-report-finds.html.

Quidel Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Stock Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related stocks with our FREE daily email newsletter.